AstraZeneca’s Etcamah gets accelerated US approval for advanced breast cancer
AstraZeneca said its breast cancer drug Etcamah (camizestrant), used with a CDK4/6 inhibitor, received accelerated approval in the US for patients with a common form of advanced breast cancer showing resistance signs.
AstraZeneca said on Monday that Etcamah (camizestrant), used with a CDK4/6 inhibitor, has received accelerated approval in the US for patients with a common form of advanced breast cancer who show signs of developing resistance to standard ho…